The National Institutes of Health (NIH) is offering a funding opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants," aimed at facilitating the clinical validation of biomarker assays related to cancer detection and treatment. This initiative encourages applications from multidisciplinary teams to adapt and validate molecular, cellular, and imaging markers, with a focus on projects that are ready for clinical integration rather than early-stage development. The funding amount is capped at $150,000 for a project period of up to three years, with eligibility extending to a wide range of organizations, including educational institutions and community-based organizations. Interested applicants should note that the submission deadlines range from January 19, 2024, to October 14, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

PAR-24-047-Full-Announcement.html

PAR-24-047.html

The National Cancer Institute (NCI) of the Department of Health and Human Services is offering a funding opportunity aimed at encouraging revision applications to validate biomarker assays developed through NIH-supported research. This initiative supports currently funded NCI R01 projects to facilitate the translation of methods and technologies to clinical use, specifically focusing on molecular, cellular, and imaging markers related to cancer detection, diagnosis, and control. Applications should involve multidisciplinary teams, including clinical lab scientists and statisticians, and target projects that are ready for clinical validation, rather than early-stage technology development. The funding is capped at $150,000 in direct costs for a maximum project period of three years, with eligibility extending to various educational, non-profit, governmental, and for-profit organizations. Key submission dates range from January 19, 2024, to October 14, 2026. Review criteria will assess the significance, investigator qualifications, innovation, and approach to the proposed projects. This funding opportunity emphasizes the integration of validated assays into clinical trials to advance cancer research and patient care.

https://grants.nih.gov/grants/guide/pa-files/PAR-24-047.html

Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as &quot;assays&quot;) to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as &quot;markers&quot; r &quot;biomarkers&quot;) for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

NIH Grants Information&lt;br/&gt;grantsinfo@nih.gov

Buyer

Award Range

Eligible Applicants

Funding Category

Funding Instrument

Opportunity Category

Cost Sharing or Matching Requirement

Original Source

Additional Information